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ARTICLE
Cervical epithelial damage promotes Ureaplasma
parvum ascending infection, intrauterine inﬂammation
and preterm birth induction in mice
Ioannis Pavlidis1*, Owen B. Spiller 2*, Gabriella Sammut Demarco1, Heather MacPherson1,
Sarah E.M. Howie 3, Jane E. Norman4 & Sarah J. Stock 1,5*
Around 40% of preterm births are attributed to ascending intrauterine infection, and Urea-
plasma parvum (UP) is commonly isolated in these cases. Here we present a mouse model of
ascending UP infection that resembles human disease, using vaginal inoculation combined
with mild cervical injury induced by a common spermicide (Nonoxynol-9, as a surrogate for
any mechanism of cervical epithelial damage). We measure bacterial load in a non-invasive
manner using a luciferase-expressing UP strain, and post-mortem by qPCR and bacterial
titration. Cervical exposure to Nonoxynol-9, 24 h pre-inoculation, facilitates intrauterine UP
infection, upregulates pro-inﬂammatory cytokines, and increases preterm birth rates from 13
to 28%. Our results highlight the crucial role of the cervical epithelium as a barrier against
ascending infection. In addition, we expect the mouse model will facilitate further research on
the potential links between UP infection and preterm birth.
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Preterm birth (PTB) is deﬁned by the World Health Orga-nisation (WHO) as any birth prior to 37 completed weeksof gestation1 ranging from 5 to 18% of all pregnancies
internationally2. PTB is the cause of 35% of the annual 3.1
million global neonatal deaths; complications of PTB are the
second most common cause of death in children under 5 years
old; and PTB carries a signiﬁcant burden of morbidity and
disability for survivors3. The potential aetiologies of PTB are
diverse4; however, at least 40% of PTB is attributed to intrau-
terine infection5. From a mechanistic perspective, infection can
trigger PTB through a cascade of events. First, the microbial
structures and products are recognised by Toll-like receptors
(TLRs) that are expressed in the decidua6, the myometrium7, the
foetal membranes8 and the placenta9 during pregnancy. Fol-
lowing receptor ligation, downstream intracellular events driven
by the transcription factors nuclear factor-κB (NF-κB)10 and
activator protein-1 (AP-1)11 lead to the increased expression of
pro-inﬂammatory cytokines, among which interleukin-1b
(IL-1b)12, IL-613, IL-814 and tumour necrosis factor-α
(TNFα)15. These cytokines can stimulate the expression of
the prostaglandin-synthesising enzyme cyclooxygenase-2
(COX-2)16 as well as the expression of matrix metalloprotei-
nases (MMPs)17. Prostaglandins are known to initiate co-
ordinated myometrial contractions and along with MMPs they
facilitate membrane rupture and cervical ripening18,19.
During pregnancy, the cervix remains closed and rigid, pro-
viding structural support to the uterine contents. At the same
time, it constitutes a physical and functional barrier that protects
the foetus against ascending infection from the bacteria-rich
vagina. The cervical epithelium is critical for this role, as it has the
ability to sense a microbial challenge by expressing TLRs20 and
stimulate the innate and adaptive immune system by producing
pro-inﬂammatory cytokines and antimicrobial peptides such as
SLPI21, Elaﬁn22 and LL-3723. It also contributes to the physical
barrier function during pregnancy through a strict temporal
regulation of the expression of tight junction proteins24 and
desmosomes25. Excisional procedures for the treatment of cer-
vical intraepithelial neoplasia (CIN) where cervical epithelium is
removed, along with underlying stroma, are commonly per-
formed and have been strongly associated with pregnancy com-
plications including PTB, yet the underlying mechanisms remain
elusive26. However, the integrity of the cervix can also be chal-
lenged by less invasive events, including alterations to the vaginal
ﬂora, viral infection and exposure to chemicals.
Ureaplasma spp. are the most common organisms isolated from
amniotic ﬂuid obtained from women who present with the PTB
antecedents of preterm labour with intact membranes; preterm
premature rupture of membranes (pPROM); short cervix associated
with microbial invasion of the amniotic cavity; as well as from
infected placentas27. Furthermore, viable Ureaplasma can be cul-
tured from 23% of cord bloods obtained from preterm neonates28,
and a recent human placenta microbiome study reported that out of
all the bacteria that they found in human placentas, Ureaplasma
spp. along with the less common Streptococcus anginosus are sig-
niﬁcantly associated with PTB29. Generally considered a low viru-
lence organism, Ureaplasma spp. has long been linked to
chorioamnionitis30 that predisposes to PTB31 and foetal injury32.
Despite repeated reports of Ureaplasma association with infertility,
early pregnancy loss, stillbirth, PTB and neonatal morbidities, it is
also true that Ureaplasma spp. can be detected in vaginal ﬂora in
40–80% of healthy women27; therefore, not all lower urogenital
tract infections lead to PTB. Consequently, it is probable that more
than one ‘insult’ is required to potentiate the likelihood of PTB.
Although systematic investigation may yet discover virulence genes
speciﬁc to PTB-associated clinical Ureaplasma strains, experimental
Ureaplasma parvum (UP) infections of pregnant macaques with the
same prototype strain have been reported to have conﬂicting out-
comes for PTB, suggesting that other experimental design differ-
ences may have potentiated the pathogenicity of Ureaplasma33,34
However, none of these experimental Ureaplasma infection models
address ascending infection from the vagina through the cervix to
the uterus as the most common route of a PTB-triggering infection
in humans35.
In this report, we examine a mouse model of ascending
infection following vaginal inoculation by UP, and characterise an
increased rate of ascending infection and PTB resulting from pre-
infection cervical exposure to N-9, a commonly used spermicide
that has been approved for use by the US Food and Drug
Administration.
Results
A model of cervical epithelial damage in mouse pregnancy. A
model of cervical epithelial insult was developed by exposing
pregnant mice (day 17 gestation of 21-day term pregnancy) to the
pharmacological spectrum of N-9 concentrations (2%, 5%, 10%
(v/v) in phosphate-buffered saline (PBS)) representative of those
used in spermicidal human contraceptives. Pregnant C57Bl6/J
mice received a 60 µL intravaginal bolus of N-9 diluted in PBS or
PBS control and the cervices harvested for investigation 8 h later.
Parafﬁn sections of the cervix were stained with Alcian Blue,
followed by periodic acid/Schiff’s reagent and a pathological score
for epithelial integrity determined for the cervix (scoring system
demonstrated in Fig. 1a). Exposure to 2%, 5% and 10% N-9
resulted in statistically signiﬁcant increases in pathological score
(Fig. 1b; 4.33 ± 0.36, P= 0.0043 for 2%; 3.89 ± 0.29, P= 0.0265
for 5%; and 4.42 ± 0.48, P= 0.0033 for 10%, mean ± standard
error of the mean (SEM), Dunnett’s multiple comparisons test)
compared to PBS controls (2.083 ± 0.37) (weighted Cohen’s κ=
0.952). Pathological scores for vaginal epithelia examined from
the same animals were similarly increased in the N-9-treated
group (Supplementary Fig. 1; 4.08 ± 0.37, P= 0.0075 for 2%; 3.56
± 0.95, P= 0.0434 for 5%; and 4.42 ± 0.34, P= 0.0033 for 10%,
Dunnett’s multiple comparisons test) compared to PBS controls
(1.54 ± 0.34) (weighted Cohen’s κ= 0.774). Further evidence of
insult to the cervix was determined by quantifying neutrophil
inﬁltration into the cervical epithelium (Fig. 2a) and cervical
stroma (Fig. 2b) by enumerating Ly-6G-stained neutrophils in
haematoxylin-counterstained parafﬁn sections. Only the highest
dose of 10% N-9 resulted in a statistically signiﬁcant increased
neutrophil inﬁltration score in the cervix of pregnant mice
(Fig. 2c; 2.75 ± 0.75, P= 0.1234 for 2%; 1.33 ± 0.33, P= 0.962 for
5%; and 3.75 ± 0.75, P= 0.0147 for 10%, Dunnett’s multiple
comparisons test) compared to PBS control (1 ± 0) (Fig. 2c)
(weighted Cohen’s κ= 0.874). These ﬁndings were similar for
neutrophil inﬁltration in the vaginal epithelium (Supplementary
Figs. 2 and 3; 4.75 ± 0.63, P= 0.0115 for 2%; 3.67 ± 1.45, P=
0.1046 for 5%; and 5.5 ± 0.5, P= 0.0032 for 10% compared to PBS
control 1.25 ± 0.25, Dunnett’s multiple comparisons test)
(weighted Cohen’s κ= 0.849).
N-9 induction of cell proliferation as an indirect indication of
cervical damage was assessed by quantifying the percentage of
proliferating basal cells (visualised by Ki-67 staining of parafﬁn
sections) in a total area of at least 1 mm per tissue section of the
cervical basement membrane (representative images shown in
Fig. 3a). Induction of increased cell proliferation, likely as a repair
response to tissue injury, was found for all three N-9 concentra-
tions (Fig. 3b; 42.21 ± 2.96, P= 0.0437 for 2%; 43.94 ± 2.66, P=
0.0298 for 5%; and 50.46 ± 3.47, P= 0.0011 for 10%, Dunnett’s
multiple comparisons test) relative to PBS controls (31.73 ± 1.2).
However, no increased cell proliferation was observed for the
vaginal epithelium (Supplementary Fig. 4).
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N-9 does not affect timing of delivery or pup survival. To
investigate whether the N-9-induced cervicovaginal toxicity
induced PTB or pup mortality, the above experiments were
repeated in pregnant mice (precisely determined to be the
morning of day 17 gestation based on timed mating/observed
cervical plug formation) along with a higher dose of 40% (v/v) to
capture the whole spectrum of a dose response. Delivery time was
deﬁned as the emergence of the ﬁrst pup (determined by review
of continuous time-stamped CCTV recording) in hours post-N-9
administration and the percentages of live-born pups for each
mouse were also determined. PBS control animals delivered an
average of 57.93 ± 2 h post procedure with 98 ± 2% of pups sur-
viving (Supplementary Fig. 5). Time to delivery and pup survival
were similar in animals exposed to 2–40% N-9 (time to delivery
60.05 ± 4.97 h, P= 0.985 for 2%; 58.1 ± 3.58 h, P= 0.999 for 5%;
64.34 ± 4.18 h, P= 0.49 for 10%; and 68.3 ± 3.66 h, P= 0.2 for
40% N-9; pup survival 97.8 ± 2.2%, P > 0.999 for 2%; 98 ± 2%, P >
0.999 for 5%; 96.75 ± 2.14%, P > 0.999 for 10%; and 90.6 ± 6.49%,
P= 0.9486 for 40% N-9, Dunnett’s multiple comparisons test).
Cervical damage facilitates ascending UP infection in preg-
nancy. To investigate whether N-9-induced cervical epithelial
challenge predisposes to ascending infection during pregnancy,
we examined the magnitude and frequency of ascending
bacterial infection following experimental vaginal inoculation of
UP. UP was chosen as this is the most frequently isolated
bacterial species associated with PTB36 and the UP strain (HPA5)
utilised has extensively been used in sheep models of intrauterine
infection37–39.
However, our UP strain used in these studies was modiﬁed by
insertion of the Promega Nanoluc® luciferase gene to enable non-
invasive in vivo imaging/quantiﬁcation of UP infection (Supple-
mentary Fig. 6), as it has been successfully used previously for
imaging Trypanosoma cruzi infection progression in mice over
126 days40. We would not anticipate NanoLuc gene insertion and
expression to alter bacterial virulence and have no evidence that it
does. In vivo UP infection was imaged by bioluminescence signal
intensity (BLI) imaging of the whole abdomen. For ascending
infection studies, pregnant mice were treated with 10% (v/v) N-9
or PBS alone in the afternoon of day 16 gestation, to allow
recovery prior to intravaginal inoculation of 2.5 × 106 infectious
units of UP-Luciferase, or sterile Ureaplasma-selective medium
(USM), in the morning of day 17 gestation. The dose of 10% (v/v)
N-9 was chosen as it was found to be the only one inducing both
morphological damage and neutrophil inﬁltrations. Visualisation
directly after administration of UP-Luciferase incubated with the
NanoLuc® substrate furimazine either vaginally or intrauterine
under ultrasound guidance generated no signal at all (Supple-
mentary Fig. 7). Twenty-four hours post infection (hpi), the
NanoLuc® substrate furimazine was administered intraperitone-
ally and luciferase signal was quantiﬁed by in vivo biolumines-
cence optical imaging using software-based signal quantiﬁcation
of the abdomen (pre-deﬁned region of interest).
Bioluminescence signals above background (set by PBS control
animal images) were demonstrated in mice infected with UP and
a representative image is shown (Fig. 4a). Mice not infected with
UP exhibited only background BLI levels (706 ± 48 counts for
control treatments PBS+USM, 734 ± 55 counts for epithelial
damage alone N-9+USM) (Fig. 4b). Higher bioluminescence
signal, representing increased bacterial load, was observed among
N-9-treated, UP-infected mice (N-9+UP; 6.12 × 104 ± 2.57 × 104
counts; P= 0.0131, unpaired t test on log-transformed biolumi-
nescence values) relative to UP-infected mice pre-treated with
PBS (no cervical damage control; PBS+UP) (9.5 × 103 ± 7.4 ×
103 counts; Fig. 4b). High-intensity signals formed the expected
shape and location of the uterus, showing bulges representing
gestating foetuses (Supplementary Fig. 8). Furthermore, the
reliable in vitro threshold of detection for UP-Luciferase was
found to be 1000 colony-forming unit (CFU)/mL when imaged
directly in a luminometer (Supplementary Fig. 9); therefore, high-
intensity signal in the in vivo setting that is detected across the
mouse abdomen would represent a substantially higher than 103
CFU/mL number of microorganisms.
Cervical damage results in higher amniotic ﬂuid UP titres. To
assess the capacity of UP to establish an infection at the admin-
istration site and whether this was affected by pre-treatment with
N-9, we quantiﬁed viable UP-Luciferase, by titration in growth
medium, ﬂushed from the vagina with PBS at 48 hpi. Inoculated
mice were found to have culturable genitourinary levels of UP-
Luciferase, ranging from 10 to 1 × 107 infectious organisms per
15 µL efﬂuent, while none of the uninfected control animals
showed growth of UP in vaginal ﬂushes. No differences in vaginal
colonisation was observed between UP-infected animals pre-
treated with N-9 or PBS ((Fig. 5; 1.3 × 106 ± 7 × 105 Colour
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Fig. 1 Intravaginal N-9 disrupts cervical epithelial morphology during
pregnancy. In the morning of D17 of gestation, mice received either N-9
(2% n= 4, 5% n= 3 or 10% n= 4 in PBS) or PBS control (n= 4) via
intravaginal inoculation. After 8 h, mice were sacriﬁced for tissue
collections. Cervical tissue sections were stained with AB/PAS and a
morphological damage scoring system was used to assess epithelial
damage (a). N-9 signiﬁcantly damages the morphology of the cervical
epithelium during pregnancy (b). Error bars indicate SD. Statistical
signiﬁcance was assessed using one-way ANOVA with Dunnett’s multiple
comparisons test against PBS group (**P < 0.005 for 2% N-9 and 10% N-9
vs. PBS, *P < 0.05 for 5% N-9 vs. PBS). Source data are provided as a
Source Data ﬁle.
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Changing Units (CCU) for PBS+UP; 1.1 × 106 ± 7 × 105 CCU of
vaginal ﬂush for N-9+UP)). However, higher UP titres were
found in the amniotic ﬂuid surrounding mouse foetuses of N-9-
pre-treated infected animals at 48 hpi, with titres (per 15 µL
amniotic ﬂuid) of 2.2 × 106 ± 7 × 105 CCU for N-9+UP vs. 7.2 ×
104 ± 3.7 × 104 CCU for PBS+UP (P= 0.0356, unpaired t test
with Welch’s correction on log-transformed titration values) in
proximal gestational sacs and 2.2 × 106 ± 8 × 105 CCU for N-9+
UP vs. 3.7 × 103 ± 2.8 × 103 for PBS+UP; P= 0.0466, unpaired
t test with Welch’s correction on log-transformed titration values)
for distal sacs (Fig. 5).
Cervical damage results in higher tissue ureC messenger RNA
(mRNA) copy number. Molecular methods of quantifying
ascending UP infection were used to complement the culture
data. Messenger RNA levels for the essential gene ureC were used
to quantify active bacterial gene transcription in frozen tissue
samples isolated from the placenta, myometrium, foetal mem-
branes and foetal lung tissues of mouse foetuses proximal and
distal to the cervix harvested at 48 hpi. ureC mRNA was not
detected in any of the tissues from mice that did not receive
intravaginal UP. Pre-treatment with N-9 followed by UP infec-
tion resulted in a higher ureC copy number in the placenta (Fig. 6;
29,490 ± 5037 copies; P= 0.0093, unpaired t test on log-
transformed values) and in the foetal membranes (Fig. 6c;
48,270 ± 7716 copies; P= 0.048, unpaired t test on log-
transformed values) in proximal gestational sacs compared to
UP-infected mice pre-treated with PBS control only (10,386 ±
2862 copies for placenta; 22,602 ± 8623 copies for foetal mem-
branes). No differences in ureC gene copy number were observed
in the foetal lung of foetuses in proximal gestational sacs (333.8 ±
190.1 copies for N-9+UP vs. 218.8 ± 108.2 copies for PBS+UP),
or in tissues from mouse foetuses in distal gestational sacs, for N-
9-pre-treated UP-infected animals compared to PBS-pre-treated
controls (Fig. 6).
Increased PTB rates on mice treated with N-9 followed by UP.
The normal time to delivery for C57Bl/6J mice from the morning
of day 17 gestation is ~60 h; therefore, we set parameters for
induction of PTB as delivery ≤48 h post-bacterial inoculation,
which was performed in the morning of day 17 (consistent with
previous studies examining LPS-induced PTB41,42). PTB rates for
N-9-pre-treated UP-infected animals (N-9+UP) were increased
(10/36; 28%; P= 0.0104, Fisher’s exact test) compared to animals
receiving PBS and sterile USM (Fig. 7; PBS+USM= 0%). PTB
was observed in 1/15 uninfected animals pre-treated with N-9 in
the absence of UP infection (N-9+USM= 6%; P= 0.4571,
Fisher’s exact test) and in 4/30 UP-infected animals in the
absence of N-9 treatment (PBS+UP= 13%; P= 0.1476, Fisher’s
exact test). Sixty-three per cent (62/98) of the spontaneously
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Fig. 2 Intravaginal N-9 results in neutrophils inﬁltrations in the cervix during pregnancy. In the morning of D17 of gestation, mice received either N-9
(2% n= 4, 5% n= 3 or 10% n= 4 in PBS) or PBS control (n= 4) via intravaginal inoculation. Eight hours later, mice were sacriﬁced for tissue collections.
Anti-Ly-6G immunohistochemistry on cervical tissue sections was used to assess the presence of neutrophils. A neutrophil inﬁltration scoring system was
used to quantify the presence of neutrophils in the cervical epithelium (a) and stroma (b), the total score being the sum of the two. Ten per cent N-9
signiﬁcantly increased the neutrophil inﬁltrations in the cervix (c). Arrowheads indicate positively stained cells. Error bars indicate SD. Statistical
signiﬁcance was assessed using one-way ANOVA with Dunnett’s multiple comparisons test against PBS group (*P < 0.05 for 10% N-9 vs. PBS). Source
data are provided as a Source Data ﬁle.
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preterm born pups (vaginally delivered) were found alive during
twice daily cage checks. However, all preterm pups were culled on
discovery in line with licence requirements and no investigations
were performed on preterm animals.
Gestational tissue cytokine response after ascending UP
infection. There is a well-established link between infection in the
uteroplacental tissues and a subsequent inﬂammatory response
driving a premature activation of the labour cascade. To explore
the effects of UP ascending infection on inﬂammation, protein
levels (enzyme-linked immunosorbent assay (ELISA)) of TNFα
and (C–X–C motif) ligand 2 (CXCL-2), and mRNA expression
(quantitative PCR (qPCR)) of the pro-inﬂammatory cytokines
TNFα, IL-1β, CXCL-1, CXCL-2 or IL-6 were examined in the
placenta, myometrium, foetal membranes and foetal lung in
frozen tissue collected at 48 hpi.
When compared to control (PBS+USM), UP infection
without prior cervical damage (PBS+UP) increased the protein
expression of cytokine TNFα in myometrium adjacent to
proximally located gestational sacs, but did not increase TNFα
or CXCL-2 protein expression in any of the other tissues
examined (Fig. 8). In contrast, when preceded by cervical damage,
UP treatment (N-9+UP) increased levels of CXCL-2 and TNFα
in the placenta of proximally and distally located gestational sacs;
CXCL-2 and TNFα in the myometrium adjacent to proximal sacs;
and CXCL-2 in the foetal membranes of proximal sacs (Fig. 8).
Fold changes in the mRNA expression of pro-inﬂammatory
cytokines relative to the control group (PBS+USM) are shown
in Fig. 9. An increased inﬂammatory response was observed in
gestational tissues in response to UP infection with (N-9+UP)
and without (PBS+UP) cervical damage. This was reﬂected in
increases in the mRNA levels of TNFα, IL-1β, CXCL-1, and
CXCL-2, myometrium and foetal membranes of the gestational
sacs most proximal to the cervix (Fig. 9). Changes were less
prominent at the distal sacs. Cervical damage followed by UP
infection (N-9+UP) was the only treatment that resulted in
increased mRNA expression of at least two cytokines in each of
the tissues examined (Fig. 9). mRNA levels of TNFα, IL-1β,
CXCL-1 and CXCL-2 in the placenta, myometrium and foetal
membranes were strongly correlated to bacterial ureC mRNA
levels (which correspond to active growth of UP; range of
Spearman’s coefﬁcients of R2= 0.71 to 0.87) irrespective of
proximal or distal position (Table 1). No intergroup differences in
pro-inﬂammatory cytokine expression were seen in the foetal
lung (results not shown).
Discussion
We have shown that cervical epithelial damage facilitates
ascending UP infection into the uteri of pregnant mice, with
accompanying PTB and elevation of pro-inﬂammatory cytokines
in the myometrium, foetal membranes and placenta. Our ﬁndings
further support the role of the vaginal commensal UP in causing
pregnancy complications by demonstrating its potential to ascend
to the gravid uterus and induce intrauterine inﬂammation.
Importantly, when preceded by cervical damage, UP infection
elicits a more robust intrauterine inﬂammatory response, which
signiﬁcantly increases the risk for PTB. This synergistic effect
between the two insults is in line with current consensus towards
PTB being a multifactorial syndrome43. Our results also highlight
the importance of the cervical epithelium in providing a protec-
tive barrier against infections in pregnancy, and provide addi-
tional rationale for the mechanisms underlying previous
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Fig. 3 Intravaginal N-9 increases basal cervical epithelial cell proliferation during pregnancy. In the morning of D17 of gestation, mice received either N-
9 (2% n= 4, 5% n= 3 or 10% n= 4 in PBS) or PBS control (n= 4) via intravaginal inoculation. At 8 h, mice were sacriﬁced for tissue collections. Anti-Ki-
67 immunohistochemistry on cervical tissue sections was used to assess cellular proliferation at the basal layer of the cervical epithelium. Representative
images are shown in a. The percentage of Ki-67-positive cells was calculated across an area covering at least 1 mm of the basal layer. N-9 signiﬁcantly
increases cellular proliferation at the cervix basal layer (b). Error bars indicate SD. Statistical signiﬁcance was assessed using one-way ANOVA with
Dunnett’s multiple comparisons test against PBS group (**P < 0.005 for 10% N-9 vs. PBS, *P < 0.05 for 2% N-9 and 5% N-9 vs. PBS). Source data are
provided as a Source Data ﬁle.
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associations between excisional treatment for carcinoma in situ
(CIN) and PTB. Cone biopsy or large loop excision of the
transformation zone involve removal of part of the cervical epi-
thelium and underlying stroma and are associated with high risk
of PTB26,44. Increased risk of PTB with larger or repeated exci-
sions has previously been reported45, but most studies have
focused on the mechanical importance of the cervix for providing
structural support, ignoring the potential role of the epithelium46.
Our studies provide empirical evidence of the importance of
epithelial integrity.
To generate a cervical epithelial damage model during preg-
nancy, we used the commonly used spermicide N-9. Our ﬁndings
of epithelial damage and neutrophil inﬁltration are in agreement
with what has been reported in non-pregnant mice47,48, rats49,
rabbits50, pigtailed macaques51 and humans52 after vaginal N-9
application. Damage has also been described in different epithelial
tissues, such as the monkey rectal tissue53. We also found that N-9
doses increased the percentage of proliferating basal cells across the
basement membrane, likely a tissue repair mechanism induced by
the epithelial injury; Catalone et al.47 reported a complete regen-
eration of the epithelium 24 h post treatment in the non-pregnant
mouse. Although this seems unlikely given the level of damage
reported at 8 h that we saw in the pregnant mouse, it does suggest
that a regeneration process is in place to compensate for the injury
being done. In addition, increased proliferation in the cervical
epithelium as a response to viral infection with herpes simplex virus
type 2 has also been shown to be part of a disorganisation process
that compromises the cervical barrier to facilitate ascending infec-
tion with Escherichia coli in pregnant mice54.
Our data conﬁrm that N-9 damages the cervical epithelium
during pregnancy, but when investigated alone it did not induce
PTB or impact foetal mortality. This suggests that cervical epi-
thelial damage in isolation is insufﬁcient to cause PTB. However,
ascending genital tract infection and subsequent inﬂammation
are the most common cause of PTB55. We found a signiﬁcant
increase in both in vivo bioluminescent imaging of ascending UP
infection and increased titres of UP (both in magnitude and
frequency of infection reaching mouse foetuses more distal from
the cervix) following N-9 cervical epithelial damage. This
demonstrates a direct relationship between cervical integrity and
ascending infection. We also found a direct correlation in both
PTB in mice with ascending infection and signiﬁcant relationship
between UP presence and increased TNFα, IL-1β, CXCL-1 and
CXCL-2 cytokine expression in foetal membranes, placenta and
the myometrium. This ﬁnding is of direct translational impor-
tance to the human pregnancy, as Ureaplasma spp. are the bac-
teria most commonly implicated in human PTB 36.
Our results are consistent with two papers both showing that
cervical epithelial damage, be it either defective epithelial differ-
entiation56 or a viral infection57, increase the risk of PTB following
vaginal E. coli administration. It is unknown whether the increase in
PTB is due to higher rates of infection or higher bacterial titres in
the presence of cervical damage; or whether cervical damage itself
actively contributes to this phenotype. In our data presented here, it
is biologically plausible that the inﬂux of neutrophils into the cer-
vical stroma caused by N-9 at least partly contributed to a patho-
logical premature cervical remodelling as previously described58.
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Fig. 5 Higher UP levels in the amniotic ﬂuid in the presence of cervical
damage. In the afternoon of D16 of gestation, mice received either 10% N-9
in PBS or PBS control via intravaginal inoculation. After 16 h, in the morning
of D17 of gestation, mice received either Ureaplasma parvum (UP) in
ureaplasma-selective medium (USM) or USM control via intravaginal
inoculation. After 48 h, in the morning of D19, vaginal ﬂushes and amniotic
ﬂuid (AF) from proximal and distal sacs were cultured in USM and UP titres
were calculated using the microplate method. There was a signiﬁcant
increase in UP titres at the proximal and distal sites in the amniotic ﬂuid of
mice pre-treated with N-9 (n= 18) compared to pre-treatment with PBS (n
= 18). No bacterial growth was detected in uninfected mice. Each dot in the
dot plots represents the average of left and right horn for each mouse at
either site. Error bars indicate SD. Statistical signiﬁcance was assessed
using unpaired t test with Welch’s correction on the log-transformed values
of Ureaplasma parvum titres for PBS+UP vs. N-9+UP at all three sites (*P
< 0.05; P= 0.0356 for amniotic ﬂuid proximal, P= 0.0466 for amniotic
ﬂuid distal). Source data are provided as a Source Data File.
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Fig. 4 Increased BLI signal by vaginal UP in the presence of cervical
damage. In the afternoon of D16 of gestation, mice received either 10% N-9
in PBS or PBS control via intravaginal inoculation. After 16 h, in the morning
of D17 of gestation, mice received either luciferease-expressing UP in
ureaplasma-selective medium (USM) or USM control via intravaginal
inoculation. After 24 h, in the morning of D18, the luciferase substrate
Furimazine was injected intraperitoneally to allow UP localisation. A
representative image is shown a. Bioluminescence signal was quantiﬁed in
a region of interest (ROI) covering each mouse’s abdomen.
Bioluminescence signal coming from luciferase-expressing UP was
signiﬁcantly increased in mice that have been pre-treated with N-9 (n= 23)
compared to PBS controls (n= 22) (b). Error bars indicate SD. Statistical
signiﬁcance was assessed using unpaired t test on log-transformed values
of bioluminescence quantiﬁcation for PBS+UP vs. N-9+UP (*P= 0.0131)
(n= 10 for PBS+USM, n= 11 for N-9+USM). Source data are provided as
a Source Data ﬁle.
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Even if not sufﬁcient to induce PTB, it could accelerate the process
driven by UP-induced intrauterine inﬂammation in PTB models.
However, our group has previously published that, in contrast to
intrauterine LPS, intravaginal administration of LPS cannot induce
PTB41. This suggests that cervical inﬂammation alone is not sufﬁ-
cient for PTB.
Regarding the pathway of infection, Racicot et al.57 have
reported using qPCR that Ureaplasma urealyticum can ascend to
the uterus and colonise the decidua, and our ﬁndings show that
closely related species U. parvum can pass through the foetal
membranes to invade the amniotic ﬂuid.
The role of cervical epithelial integrity is also supported by
previous reports showing that inappropriate differentiation of
cervical epithelial cells predisposed to ascending infection with E.
coli at day 16 gestation, resulting in PTB rates of 4/8 for 107 CFU
and 3/11 for 105 CFU56. Herpes simplex virus-2 infection of the
cervical epithelial cells has also been shown to increase PTB rates
from 2/6 after a subsequent vaginal administration of 105 CFU E.
coli to 7/954. Given the small numbers of wild-type animals in
both studies, the rates of PTB are comparable to our rates of 4/30
in UP only and 10/36 for N-9+UP. Our UP infection rates are
more representative of Ureaplasma spp. associated PTB in patient
populations (E. coli is not commonly reported to be associated
with PTB), and suggests that ascending Ureaplasma spp. infection
may prove to be a better model for the future. In contrast to E.
coli, Ureaplasma spp. is a very low virulence common vaginal
commensal with a prevalence of around 40%59 and is the most
common organism found in PTB. Our PTB rates of 28% are also
similar to PTB rates reported in a retrospective study of women
with a short cervix and intrauterine Ureaplasma spp. infection60.
Induction of PTB is largely a consequence of an infection-
mediated inﬂammatory response. Therefore, we examined
expression of key cytokines in the foetal membranes, placenta and
myometrium for infected and uninfected pregnant mice. While
no increase in acute inﬂammatory cytokine IL-6 was found, gene
expression levels of TNFα and IL-1β were increased, as were
neutrophil-recruiting cytokines CXCL-1 and CXCL-2. Correlat-
ing the levels of cytokine expression relative to the levels of UP-
derived gene ureC expression (a key subunit of the urease enzyme
complex) identiﬁed a strong and signiﬁcant relationship in the
respective tissues. Increased gene expression was substantiated by
increased ELISA measurements for CXCL-2 and TNFα as well.
Previous studies, where UP was administered in the intrauterine
compartment, have reported similar upregulation of
cytokines61,62; however, our studies are more relevant to patients,
as we have administered UP by ascending infection from the
vagina rather than injecting UP or UP-derived lipoproteins
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Fig. 6 Higher UP levels in gestational in the presence of cervical damage. In the afternoon of D16 of gestation, mice received either 10% N-9 in PBS or
PBS control via intravaginal inoculation. After 16 h, in the morning of D17 of gestation, mice received either Ureaplasma parvum (UP) in ureaplasma-selective
medium (USM) or USM control via intravaginal inoculation. After 48 h, in the morning of D19, gestational tissues were analysed for ureCmRNA expression.
In mice pre-treated with N-9 (n= 7), there was a signiﬁcant increase in ureC copy number at the proximal sites of the placenta and the foetal membranes
compared to pre-treatment with PBS (n= 6) and a trend increase in all other tissues and sites (a–d). No ureC copies were detected in uninfected mice.
Each dot in the dot plots represents the average of left and right horn for each mouse at either site. Error bars indicate SD. Statistical signiﬁcance was
assessed using unpaired t test for PBS+UP vs. N-9+UP in all four tissues and at both sites (*P= 0.048 for N-9+UP vs. PBS+UP at the foetal
membranes’ proximal site, **P= 0.0093 for N-9+UP vs. PBS+UP at the placental proximal site). Source data are provided as a Source Data ﬁle.
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Fig. 7 Increased PTB rates in the presence of cervical damage. In the
afternoon of D16 of gestation, mice received either 10% N-9 in PBS or PBS
control via intravaginal inoculation. After 16 h, in the morning of D17 of
gestation, mice received either Ureaplasma parvum (UP) in ureaplasma-
selective medium (USM) or USM control via intravaginal inoculation.
Signiﬁcantly increased PTB rates compared to controls (deﬁned as delivery
of the ﬁrst pup before up to 48 h after UP administration) was only seen
with the combination treatment of N-9+UP. No bacterial growth or ureC
copies were detected in uninfected mice. Statistical signiﬁcance was
assessed using Fisher’s exact test (*P= 0.0104 for PBS+USM vs. N9+
UP). Source data are provided as a Source Data ﬁle.
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directly into the uterine horn. UP-mediated cytokine upregula-
tion appears to be mediated via TLR signalling. In vitro studies
using a range of cells, including human kidney cells63, cord blood
monocytes64 and human amniotic epithelial cells65, have shown
upregulation of TNFα, IL-1β, IL-6 and IL-8 (the latter being the
human ortholog of CXCL-1 and CXCL-2). Use of small inter-
fering RNA to knock down TLR responses to UP in human
amniotic epithelial cells have identiﬁed a key role for TLR2, TLR6
and TLR9 in cytokine induction. This could be the pathway of
Ureaplasma spp.-induced PTB, as these cytokines are known
stimulators of the labour-inducing prostaglandins E2 and F2a and
their synthesising enzyme COX-266,16. Furthermore, induction of
several MMPs, known to be important to parturition remodelling
of the cervix for birth by cytokines has also been reported17,67.
Increased amniotic ﬂuid MMP-9 levels have been reported for
UP-positive spontaneous PTBs, but not with induced PTB or
spontaneous PTB with negative Ureaplasma cultures68.
In summary, our data highlight the critical role of the cervical
epithelium in the barrier function of the cervix against ascending
infection and PTB. We also report increased PTB rates after
vaginal infection with UP in the mouse. The ﬁnding that cervical
epithelial damage facilitates ascending vaginal tract infection and
amniotic ﬂuid colonisation with UP recapitulates established
clinical scenarios and suggests a mechanism explaining why
women undergoing excisional treatment of the cervix for CIN are
at increased risk for a subsequent preterm delivery. Cervical
epithelial integrity appears to be vital for protecting against
infection and contributes to a successful pregnancy outcome.
While current treatment options for PTB are being proven inef-
fective, our ﬁndings are of signiﬁcant translational importance in
the design of future PTB prevention strategies.
Methods
Animal studies. All animal studies were performed under UK Home Ofﬁce
License 70/8927 (PPL) to J.E.N. and in accordance with the ethical regulations for
animal testing and research as set out by the UK Animals (Scientiﬁc Procedures)
Act of 1986. All proposed experiments and procedures were reviewed against the
Home Ofﬁce Licence and approved by the Named Training and Competency
Ofﬁcer and Named Veterinary Surgeon of the Bioresearch and Veterinary Services
of University of Edinburgh. No unexpected adverse events were noted ensuring no
breach of the Project Licence Protocols. Speciﬁc pathogen-free virgin female C57Bl/
6J mice (strain code: 632) were purchased from Charles River Laboratories
(Margate, UK) at 6–8 weeks of age. They were housed under tightly regulated
temperature (19–23 °C), humidity (55%) and light (12 h dark/light cycles) condi-
tions. Mice were acclimatised for 10 days and then time mated. Conﬁrmation of
successful pregnancy was equated to vaginal plug presence at day 1 of pregnancy.
Five mice were housed in one conventional cage with regular bedding changes and
24-h access to food and water until the day they would undergo an experimental
procedure. Following the procedure, mice were housed in individual conventional
cages in an isolated room under CCTV monitoring and under the same husbandry
conditions. Pathogen-free status of the housing facility is conﬁrmed by regular
cleaning/sterilisation of all rooms with quarterly harvest of sentinel animals in each
housing area to conﬁrm the absence of speciﬁed pathogen transmission.
Ureaplasma parvum culture. Ureaplasma parvum strain HPA5 (sub-strain 137a1,
which was recovered from the amniotic ﬂuid of a pregnant sheep following
experimental UP infection with HPA5 for 5 weeks) was cultured in USM
(Mycoplasma Experience Ltd. Reigate, UK)69. Viable bacteria were quantiﬁed by
10-fold dilution (series of 15 µL in 135 µL) of inoculation stocks, vaginal ﬂushes or
amniotic ﬂuid samples in USM in sterile 96-well plates (Elkay, Basingstoke, UK),
sealed with clear adherent sealing ﬁlm (Elkay, Basingstoke, UK) following incu-
bation at 37 °C for 48 h. For post-infection quantiﬁcation, all values are calculated
for bacterial load in the 15 µL of amniotic ﬂuid or vaginal ﬂush, for inoculating
stocks values were calculated per mL of stock. A large-scale stock for inoculation
was prepared by collecting mid-log phase growth UP after overnight incubation as
previously described for experimental in utero pregnant sheep studies39. Inocu-
lating stock was divided into 200 µL aliquots and sufﬁcient aliquots were freshly
thawed for the required number of mice to be infected in each batch of pregnant
Fig. 8 Cytokine protein levels in gestational tissues following vaginal UP
infection. In the afternoon of D16 of gestation, mice received either 10% N-
9 in PBS or PBS control via intravaginal inoculation. After 16 h, in the
morning of D17 of gestation, mice received either Ureaplasma parvum (UP)
in ureaplasma-selective medium (USM) or USM control via intravaginal
inoculation. Tissues were collected 48 h later, protein extracted and
analysed using ELISA. Mice that were infected with U. parvum than had a
previously damaged cervical epithelium (n= 7) demonstrated an increase
in the protein levels of CXCL-2 (a, e, i) and TNFα (c, g) at the proximal site
of the placenta, myometrium and membranes compared to vehicle-treated
controls (n= 6). At the distal site, there was a difference in the expression
of CXCL-2 (b) and TNFα (d) in the placenta, but not the myometrium or the
membranes (f, h, j). Error bars indicate SD. Statistical signiﬁcance of the
treatment effect was assessed using Dunnett’s multiple comparisons test
against the PBS+USM group for CXCL-2 and Dunn’s multiple comparisons
test against the PBS+USM group for TNFα (*P < 0.05, **P < 0.01) (n= 6
for N-9+USM and PBS+UP) (ND: not detected). Source data are
provided as a Source Data ﬁle.
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mice (aliquots were never refrozen). In contrast to the previous sheep studies, the
HPA5 strain of serovar 3 U. parvum was genetically manipulated to express the
Promega NanoLuc® luciferase gene by site-directed mutagenesis with mini-
transposon pMT85 using methods previously described70. The altered pMT85
plasmid contained two copies of NanoLuc® luciferase, preceded by the promoter
from U. parvum tufA gene (synthesised by GenScript, Piscataway, NJ) subcloned
into the XbaI site in pMT85; the sequence of the entire plasmid is available at
GenBank (accession number MN275117). Threshold of detection following incu-
bation of UP-Luciferase with Promega Nano-Glo® Live Cell Assay substrate was
found to be equivalent to 1000 bacteria in vitro (Supplementary Fig. 9). Image
acquisition was tested following incubation of UP-Luciferase with Promega Nano-
Glo® Live Cell Assay substrate and associated controls for our in vivo experiments
(Supplementary Fig. 10).
Mouse model of cervical damage. In the morning of day 17 gestation, mice were
anaesthetised by isoﬂurane inhalation (5% for induction of anaesthesia, 2.5% for
maintenance) and a pipette was used for intravaginal administration of either N-9
(60 μl; 2%, 5%, 10% (v/v) in PBS or PBS alone). Mice were randomly assigned to
each group. Care was taken to minimise vaginal leakage of administered bolus, and
leakage was monitored by examining dry tissue placed under mice during anaes-
thesia recovery. Only minor leakages (dampening of tissue) were observed. Mice
were returned to individual cages and tissues were harvested for examination at 8 h
post treatment.
Mouse model of cervical damage and ascending infection. In the afternoon of
day 16 gestation, mice were anaesthetised and received either 10% (v/v) N-9 or PBS
as above, monitored for leakage during recovery and returned to individual cages.
In the morning of day 17 gestation, mice were re-anaesthetised and received a
further vaginal inoculation of either UP-Luciferase (40 μl aliquot of 108 CCU/ml in
USM) or 40 μl USM alone. Mice were randomly assigned to each group. To reduce
the likelihood of cross-contamination, the group of mice that was treated with UP-
Luciferase was handled last. Following successful recovery from anaesthesia, mice
were put in individual cages to monitor the time to delivery by continual CCTV
(including recording for accurate determination of emergence of ﬁrst pup). Pre-
term delivery was determined as birth occurring <48 h post infection (or mock
infection) as normal term delivery is known to be ~60 h from this point. Mice that
have not delivered by the 48-h mark after administration of UP-Luciferase
(completed day 18 of gestation) were deemed as term and were sacriﬁced for
collection of antepartum tissues. Rapid caesarean delivery of near-term foetuses
was performed under terminal anaesthesia as speciﬁed by our animal licence;
therefore, no assessment for foetal viability could be made. During this period, they
also received twice daily physical health checks for signs of potential adverse effects
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Fig. 9 Cytokine mRNA levels in gestational tissues following vaginal UP infection. In the afternoon of D16 of gestation, mice received either 10% N-9 or
PBS control via intravaginal inoculation. After 16 h, in the morning of D17 of gestation, mice received either UP or USM control via intravaginal inoculation.
Tissues were collected 48 h later and analysed using RT-qPCR. Mice that were infected with UP (PBS+UP, n= 6; N-9+UP, n= 7) had an increase in the
mRNA levels of TNFα (a, e, i), IL-1β (b, f, j), CXCL-1 (c, g, k) and CXCL-2 (d, h, l) compared to vehicle-treated controls (PBS+USM, n= 6). The effect was
stronger at the proximal site. Error bars indicate SD. Statistical signiﬁcance of the treatment effect was assessed using Dunnett’s multiple comparisons test
on the DDCt values against the PBS+USM group for the proximal and distal site. Statistical signiﬁcance for the site effect was assessed unpaired t test for
proximal vs. distal for each treatment group (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) (n= 6 for N-9+USM). Source data are provided as a
Source Data ﬁle.
Table 1 Correlation between ureC andgene expression changes.
Cytokines Placenta Uterus Foetal Membranes
TNFα 0.51 (P < 0.01) 0.76 (P < 0.001) 0.84 (P < 0.001)
IL-1β 0.72 (P < 0.001) 0.79 (P < 0.001) 0.78 (P < 0.001)
CXCL-1 (IL-8 homologue) 0.71 (P < 0.001) 0.80 (P < 0.001) 0.70 (P < 0.001)
CXCL-2 (IL-8 homologue) 0.78 (P < 0.001) 0.84 (P < 0.001) 0.87 (P < 0.001)
IL-6 0.2 0.02 0.39 (P < 0.01)
Values are (Spearman’s R2) with signiﬁcance values of correlation within parentheses
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and to check for preterm born mice, which were recorded and immediately culled
in line with the requirements of the animal licence.
In vivo imaging for luciferase. Animals in the above group were imaged in vivo
for ascending infection and determination of bacterial load 24 h after infection with
UP-Luciferase. The abdomens of anaesthetised mice were shaved prior to imaging
to minimise signal interference through absorbance, scattering or diffraction of
light by the mouse fur and 100 μl of the luciferase substrate Furimazine (Nano-
Glo® Live Cell Assay System, Promega, Madison, WI, USA) was administered
intraperitoneally. Optical imaging was carried out using the facilities of the
Edinburgh Preclinical Imaging, College of Medicine and Veterinary Medicine,
University of Edinburgh. Speciﬁcally, mice were placed in a PhotonIMAGERTM
OPTIMA for optical imaging (Biospace Lab, Nesles-la-Vallee, France). Lumines-
cence was quantiﬁed by integral photon counting technology based on intensiﬁed
charge-coupled devices, allowing real-time display of the bioluminescence signal
and recording of kinetics information.
In vivo imaging analysis. Imaging analysis was performed using the M3 Vision
software (Biospace Lab, Nesles-la-Vallee, France). A standardised elliptical region
of interest template was applied to the image of each mouse’s abdomen, including
the lower abdomen and the cervix, and Photo Acquisition software measurements
determined the plateau phase of signal kinetics prior to performing quantiﬁcation
analysis. Measurements were provided as photons per second per centimetre
square per steradian (ph/s/cm2/sr). This unit normalises for differences in the
mouse size and position on the stage as well as the time frame used for the
quantiﬁcation analysis.
Tissue collections. For the cervical damage model, the vagina, the cervix and part
of the myometrium were collected as a single continuous tissue and, after the
surrounding fat was trimmed off, they were immediately transferred to 4% par-
aformaldehyde for ﬁxation. Tissues were then embedded in parafﬁn blocks for
immunohistochemical analysis. To accurately assess tissue damage, we deployed
the following strategy for processing and analysing our samples: three consecutive
5-μm-thick longitudinal sections (used for histology, Ly-6G and Ki-67 immuno-
histochemistry, respectively) from three different levels of the lower reproductive
tract were processed, each level 50 μm deeper than the preceding one. Subsequently
obtained scores for each mouse represent the average of the scores for the three
different levels.
For the cervical damage and ascending infection model, the following tissues
were collected and snap frozen in dry ice from all term dams: vaginal ﬂush (60 μl of
PBS were ﬂushed into the vagina right after the mouse was culled) and cervix. Four
foetuses were chosen for tissue collections from each term dam, two from each
horn: the one closest to the cervix (proximal) and the one furthest from the cervix
(distal). The following tissues were collected and snap frozen in dry ice from all
term foetuses: amniotic ﬂuid, placenta, myometrium (whole part of uterus
surrounding the foetus), foetal membranes and foetal lung. Unless used
immediately, tissues were cut in half and stored in −80 °C for qPCR and protein
analysis.
Parafﬁn section processing. Slides were deparafﬁnised in xylene (Cell Path Ltd,
Newtown, UK) and rehydrated in sequential immersion in 100%, 95%, 80%, 70%
and ethanol. For histological grading, slides were then immersed in 1% Alcian Blue
for 10 min. Following this, slides were rinsed in deionised H2O and were then
oxidised in an aqueous solution of 0.5% periodic acid for 10–20 min. After a rinse
in deionised H2O, slides were treated with Schiff’s reagent for the same length of
time and then immersed in Harris’ haematoxylin (Cell Path Ltd., Newtown, UK),
for 30 s. Slides were then placed in Scott’s Tap Water Substitute until sections
turned blue. For immunohistology, slides were immersed in sodium citrate buffer
(10 mM sodium citrate, pH 6.0 in distilled H2O) and heated to sub-boiling using an
InstantPot IP-LUX60 6L/6.33Qt Pressure Cooker (InstantPot, Ottawa, Canada) to
unmask antigens. Endogenous peroxidases were removed with 3% hydrogen per-
oxide treatment for 30 min and non-speciﬁc binding removed by incubation with
5% (v/v) normal goat serum. Polymorphonuclear neutrophils were stained with
puriﬁed rat anti-mouse Ly-6G (lymphocyte antigen 6 complex, locus G) (1:500 in
blocking solution, BioLegend, San Diego, USA), while proliferating cells were
stained with rabbit anti-Ki-67 (ab15580, 1:1000 in blocking solution, Abcam,
Cambridge, UK), by overnight incubation at 4 °C. Primary antibody binding was
visualised by ImmPRESS horse radish peroxidase (HRP) anti-rat IgG or anti-rabbit
IgG HRP-conjugated secondary antibodies (Vector Laboratories, Peterborough,
UK), followed by reaction with 3,3′- diaminobenzidine and counterstained with
Harris’ haematoxylin. Slides were then dehydrated in ethanol followed by xylene
and sealed with cover slips.
Histological imaging analysis. Imaging of the samples was performed on a Zeiss
Axio Scan.Z1 Slide Scanner (Carl Zeiss AG, Oberkochen, Germany). Imaging
analysis was performed using the Zeiss ZEN Blue software (Carl Zeiss AG). This
allows for individual operator-led analysis of the images obtained by the slide
scanner. Speciﬁcally, two independent assessors that were blinded to treatment
allocation evaluated all images based on the scoring systems described in the
respective Results sections. Individual scores for each mouse represent the average
of the scores assigned by the assessors. Inter-rater reliability was assessed using
weighted Cohen’s κ.
Quantitative PCR. Total RNA was extracted from the placenta, myometrium,
foetal membranes and foetal lung tissue collected at the 48 h time point by using
the RNeasy mini kit (Qiagen, Crawley, UK) following the manufacturer’s
instructions. Total RNA (500 ng) was reverse transcribed using the High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life Technolo-
gies Ltd., Paisley, UK). Pre-designed gene expression assays from Applied Bio-
systems were used to examine the expression of CXCL-1 (Mm04207460_m1),
CXCL-2 (Mm00436450_m1), IL-1β (Mm00434228_m1), IL-6 (Mm00446190_
m1) and TNFα (Mm99999068_m1). Target gene expression was normalised for
RNA loading by using β-actin, and the expression in each sample was calculated
relative to the average of the calibrator group (mice treated with PBS+USM).
All qPCR analyses were performed on an Applied Biosystems 7900HT instru-
ment. Data were analysed using the 2−ΔΔCt method. ureC gene expression by
HPA5-Luciferase in these samples was quantiﬁed by using primers (UUP_FP,
AAGGTCAAGGTATGGAAGATCCAA and UUP_RP, TTCCTGTTGCCCC
TCAGTCT) and probe (UP_HP, (HEX)-TCCACAAGCTCCAGCAGCAATT
TG-(BHQ1)), and absolute copy number of mRNA species determined against a
standard curve of 10–1,000,000 copies of a plasmid containing the ureC gene
(GenBank accession number NC_010503.1) synthesised by GenScript
(Piscataway, NJ)
Enzyme-linked immunosorbent assay. Total tissue protein was extracted from
the placenta, myometrium and foetal membranes tissues collected at the 48 h time
point and quantiﬁed using a commercial assay and according to the manufacturer’s
instructions (Bio-Rad, Hercules, USA). Total protein concentration was adjusted to
3 mg/mL for all samples using ELISA reagent diluent. The levels of CXCL-2 and
TNFα were measured using ELISA kits and according to the manufacturer’s
instructions (R&D Systems, Abington, UK).
Statistical analysis. Data are expressed as the mean value of individual groups ±
standard deviation (SD), as indicated by error bars, and presented as mean ±
standard error of the mean (SEM) in the text. Bioluminescence and amniotic ﬂuid
titres were log transformed before analysis and the proportion of live-born pups
was arc-sin transformed before analysis. Statistical analysis was performed using
the GraphPad Prism 7.0 software (GraphPad, San Diego, CA). Statistical sig-
niﬁcance in differences between experimental groups was assessed by one-way
analysis of variance with Dunnett’s multiple comparison test or by unpaired t test
with Welch’s correction on log-transformed values or by Fisher’s exact test for
proportions. To determine whether the samples in our populations were normally
distributed, a D′ Agostino–Pearson omnibus normality test was performed. All
statistical tests were performed as two-way analyses. All measurements included in
this study were taken from distinct samples.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All raw data from the ﬁgures of this manuscript are provided as a Data Source File and
may additionally be accessed at https://doi.org/10.7488/ds/2719.
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